Trial Profile
A Phase III, Open-Label Clinical Trial to Study the Safety and Pharmacokinetics of MK-0476 in Japanese Pediatric Subjects Aged 1 to 15 Years Old With Perennial Allergic Rhinitis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 May 2022
Price :
$35
*
At a glance
- Drugs Montelukast (Primary)
- Indications Perennial allergic rhinitis
- Focus Adverse reactions; Pharmacokinetics; Registrational
- Sponsors Merck Sharp & Dohme; Organon
- 10 Jan 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 21 Oct 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 01 Jun 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.